Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:26 am
Author: Getaka|Social: XLinkedIn

Orchid Pharma Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹1,698.35Undervalued by 227.24%vs CMP ₹519.00

P/E (101.0) × ROE (8.2%) × BV (₹251.00) × DY (2.00%)

₹725.52Undervalued by 39.79%vs CMP ₹519.00
MoS: +28.5% (Adequate)Confidence: 59/100 (Moderate)Models: 1 Under, 7 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹2,360.8126%Under (+354.9%)
Graham NumberEarnings₹144.7516%Over (-72.1%)
Earnings PowerEarnings₹85.1013%Over (-83.6%)
DCFCash Flow₹36.2913%Over (-93%)
Net Asset ValueAssets₹251.038%Over (-51.6%)
EV/EBITDAEnterprise₹306.2010%Over (-41%)
Earnings YieldEarnings₹37.108%Over (-92.9%)
Revenue MultipleRevenue₹272.506%Over (-47.5%)
Consensus (8 models)₹725.52100%Undervalued
Key Drivers: EPS CAGR 39.0% lifts DCF — verify sustainability. | P/E of 101 makes PE-ROE unreliable — asset/earnings models are better benchmarks.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 39.0%

*Investments are subject to market risks

Investment Snapshot

35
Orchid Pharma Ltd scores 35/100 (Weak)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health53/100 · Moderate
ROCE 8.1% AverageROE 8.2% AverageD/E 0.65 ModerateInterest Coverage 0.0x RiskyProfitable 3/5 years Mixed
Smart Money20/100 · Weak
FII holding down -1.52% (6mo) SellingDII holding down 0.72% MF sellingPromoter holding at 69.8% Stable
Earnings Quality40/100 · Moderate
OPM stable around 14% SteadyWorking capital: 135 days Capital intensive
Quarterly Momentum15/100 · Weak
Revenue (4Q): -10% YoY DecliningProfit (4Q): -84% YoY DecliningOPM: 1.0% (down 11.0% YoY) Margin pressure
Industry Rank30/100 · Weak
P/E 101.0 vs industry 53.8 Premium to peersROCE 8.1% vs industry 16.4% Below peers3Y sales CAGR: 18% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:26 am

Market Cap 2,634 Cr.
Current Price 519
Intrinsic Value₹725.52
High / Low 899/471
Stock P/E101
Book Value 251
Dividend Yield0.00 %
ROCE8.07 %
ROE8.21 %
Face Value 10.0
PEG Ratio2.59

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Orchid Pharma Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Orchid Pharma Ltd 2,634 Cr. 519 899/471101 2510.00 %8.07 %8.21 % 10.0
Gujarat Themis Biosyn Ltd 2,692 Cr. 247 479/22256.3 24.30.27 %27.3 %21.7 % 1.00
Bliss GVS Pharma Ltd 2,427 Cr. 229 244/10522.0 1070.22 %11.7 %8.36 % 1.00
Gufic BioSciences Ltd 2,895 Cr. 289 409/26857.3 62.70.03 %13.2 %12.3 % 1.00
Dishman Carbogen Amcis Ltd 2,291 Cr. 146 322/12817.4 4060.00 %2.42 %0.32 % 2.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Orchid Pharma Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 160210183199221217244223217237173194207
Expenses 146170161175185188212192191209159195206
Operating Profit 1440222335293230262814-12
OPM % 9%19%12%12%16%13%13%14%12%12%8%-1%1%
Other Income 9342881388841111-2
Interest 8764434344343
Depreciation 8788988999999
Profit before tax 759112030302826221914-3-12
Tax % 0%0%0%0%0%-10%-1%0%0%-0%0%0%0%
Net Profit 85992029332927212215-6-13
EPS in Rs 1.8614.491.853.905.806.505.795.374.104.392.94-1.13-2.49

Last Updated: March 3, 2026, 3:57 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 6:46 am

MetricSep 2013n n 18mMar 2015n n 18mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1,9481,747873797683600484450560666819922811
Expenses 1,8371,429703794659612515421505581708804769
Operating Profit 110317171324-12-3129558411111842
OPM % 6%18%20%0%4%-2%-6%7%10%13%14%13%5%
Other Income 92156-28-592021824156752312725
Interest 52353729434731076523333171514
Depreciation 2523251451411331301181098755333535
Profit before tax -573-389-296-544-39969-131-117248929617
Tax % -2%-49%-6%-9%-12%0%0%0%0%0%-3%-0%
Net Profit -560-197-279-495-35369-131-117-2469210019
EPS in Rs -79.21-23.06-31.37-55.69-39.657.80-32.11-28.55-0.4811.3518.1719.653.71
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-77.42%28.69%119.55%-289.86%10.69%98.29%2400.00%100.00%8.70%
Change in YoY Net Profit Growth (%)0.00%106.11%90.86%-409.40%300.54%87.60%2301.71%-2300.00%-91.30%

Orchid Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:-6%
5 Years:14%
3 Years:18%
TTM:-3%
Compounded Profit Growth
10 Years:9%
5 Years:23%
3 Years:249%
TTM:-24%
Stock Price CAGR
10 Years:30%
5 Years:%
3 Years:33%
1 Year:-51%
Return on Equity
10 Years:%
5 Years:2%
3 Years:7%
Last Year:8%

Last Updated: September 5, 2025, 11:55 am

Balance Sheet

Last Updated: December 4, 2025, 1:45 am

MonthSep 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 70858989898941414141515151
Reserves 310244-40-556-881-7937256126076481,1191,2171,223
Borrowings 3,2043,2113,2153,1063,2023,230566453268331135175282
Other Liabilities 1,067521598616715551128132195205249246167
Total Liabilities 4,6514,0613,8623,2563,1253,0771,4601,2371,1111,2251,5541,6881,722
Fixed Assets 2,5841,7951,6371,4971,3861,256858670584573620633631
CWIP 36028228028827227826710463181120
Investments 1111100154544465049
Other Assets 1,7061,9841,9441,4701,4671,542576544472561857925922
Total Assets 4,6514,0613,8623,2563,1253,0771,4601,2371,1111,2251,5541,6881,722

Reserves and Borrowings Chart

Cash Flow

MonthSep 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 168-3692124019128124921812619
Cash from Investing Activity + -9861,334-1-176-284516767113-31-312-27
Cash from Financing Activity + 664-597-286-46533-0-250-165-2173116725
Net Cash Flow -153367-76-2401557-2-74-1118-1918
Free Cash Flow -871965211392357723238-861-131
CFO/OP 153%-102%124%13,628%67%-138%-226%63%173%22%113%17%

Free Cash Flow

MonthMar 2015n n 18mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2013n n 18m
Free Cash Flow317.00168.000.0021.00-15.00-597.00-424.00-213.00-247.00-24.00-57.00110.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthSep 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 3454130756473511101111188796
Inventory Days 187118220196202214254244201217199219
Days Payable 220146341402374381182176195165173149
Cash Conversion Cycle -0269-130-108-94123179117170113166
Working Capital Days -399-49-168-500-876-1,1581663029754118135
ROCE %-3%1%1%-4%-4%-5%-6%-5%-2%5%9%8%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 89.96%72.40%72.40%69.84%69.84%69.84%69.84%69.84%69.84%69.84%69.84%69.84%
FIIs 0.81%8.58%8.08%4.14%1.96%1.42%1.94%2.53%2.69%1.39%1.56%1.17%
DIIs 2.62%13.48%12.46%14.51%17.73%18.93%18.30%19.00%20.10%19.43%19.04%19.38%
Public 6.60%5.54%7.05%11.52%10.47%9.82%9.94%8.63%7.37%9.34%9.57%9.61%
No. of Shareholders 29,52329,13229,19736,93136,72034,69536,36334,15834,30339,82738,15535,709

Shareholding Pattern Chart

No. of Shareholders

Orchid Pharma Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Quant Small Cap Fund 3,465,947 0.88 242.31,534,9192025-12-07 17:25:17125.81%
Invesco India Contra Fund 990,763 0.35 69.26N/AN/AN/A
Kotak Multi Asset Allocation Fund 942,962 0.54 65.92689,0172026-02-21 15:51:0336.86%
UTI Value Fund 787,231 0.56 55.04745,2302026-02-23 01:48:215.64%
Invesco India Smallcap Fund 455,183 0.35 31.82N/AN/AN/A
Kotak Special Opportunities Fund 427,811 2.1 29.91N/AN/AN/A
Bandhan Small Cap Fund 310,553 0.11 21.71294,2012026-01-26 08:21:045.56%
UTI Small Cap Fund 283,362 0.44 19.81445,0002025-12-08 01:35:25-36.32%
Kotak Consumption Fund 266,000 1.13 18.6N/AN/AN/A
Kotak Multicap Fund 264,308 0.08 18.48114,3082026-01-25 05:51:32131.22%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 19.6519.0611.35-0.48-28.55
Diluted EPS (Rs.) 19.6519.0611.35-0.48-28.55
Cash EPS (Rs.) 25.6925.3025.3021.71-1.87
Book Value[Excl.RevalReserv]/Share (Rs.) 249.86230.58168.72158.61159.96
Book Value[Incl.RevalReserv]/Share (Rs.) 249.86230.58168.72158.61159.96
Revenue From Operations / Share (Rs.) 181.77161.55163.14137.09110.26
PBDIT / Share (Rs.) 28.5227.9125.2515.2215.93
PBIT / Share (Rs.) 21.7121.3511.82-6.10-10.76
PBT / Share (Rs.) 18.8418.1313.54-13.94-23.34
Net Profit / Share (Rs.) 18.8818.7411.880.38-28.55
NP After MI And SOA / Share (Rs.) 19.6518.1711.35-0.47-28.55
PBDIT Margin (%) 15.6917.2715.4711.1014.44
PBIT Margin (%) 11.9413.217.24-4.44-9.75
PBT Margin (%) 10.3611.228.29-10.16-21.16
Net Profit Margin (%) 10.3811.607.270.28-25.89
NP After MI And SOA Margin (%) 10.8011.246.95-0.34-25.89
Return on Networth / Equity (%) 7.867.886.72-0.30-17.84
Return on Capital Employeed (%) 7.858.375.65-2.86-4.00
Return On Assets (%) 5.905.933.78-0.17-9.41
Long Term Debt / Equity (X) 0.100.100.210.320.65
Total Debt / Equity (X) 0.130.110.480.410.65
Asset Turnover Ratio (%) 0.560.580.570.470.30
Current Ratio (X) 2.833.041.351.873.87
Quick Ratio (X) 1.682.030.731.152.79
Inventory Turnover Ratio (X) 3.122.142.022.091.60
Interest Coverage Ratio (X) 9.958.653.201.941.27
Interest Coverage Ratio (Post Tax) (X) 7.596.811.50-0.77-0.85
Enterprise Value (Cr.) 3934.975169.071869.701420.3010472.28
EV / Net Operating Revenue (X) 4.276.312.812.5423.27
EV / EBITDA (X) 27.2036.5218.1422.86161.10
MarketCap / Net Operating Revenue (X) 4.276.472.362.0722.36
Price / BV (X) 3.114.532.281.7915.41
Price / Net Operating Revenue (X) 4.276.472.362.0722.36
EarningsYield 0.020.010.020.00-0.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Orchid Pharma Ltd. is a Public Limited Listed company incorporated on 01/07/1992 and has its registered office in the State of Tamil Nadu, India. Company's Corporate Identification Number(CIN) is L24222TN1992PLC022994 and registration number is 022994. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 921.93 Cr. and Equity Capital is Rs. 50.72 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsPlot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Alathur, Chengalpattu Tamil Nadu 600110Contact not found
Management
NamePosition Held
Mr. Ram Gopal AgarwalChairman & Non-Exe.Director
Mr. Manish DhanukaManaging Director
Mr. Mridul DhanukaWhole Time Director
Mr. Arjun DhanukaNon Executive Director
Mrs. Tanu SinglaIndependent Woman Director
Dr. Dharam VirIndependent Director
Dr. Manoj Kumar GoyalIndependent Director
Ms. Shubha SinghIndependent Woman Director

FAQ

What is the intrinsic value of Orchid Pharma Ltd and is it undervalued?

As of 10 April 2026, Orchid Pharma Ltd's intrinsic value is ₹725.52, which is 39.79% higher than the current market price of ₹519.00, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (8.21 %), book value (₹251), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Orchid Pharma Ltd?

Orchid Pharma Ltd is trading at ₹519.00 as of 10 April 2026, with a FY2026-2027 high of ₹899 and low of ₹471. The stock is currently near its 52-week low. Market cap stands at ₹2,634 Cr..

How does Orchid Pharma Ltd's P/E ratio compare to its industry?

Orchid Pharma Ltd has a P/E ratio of 101, which is above the industry average of 53.84. The premium over industry average may reflect growth expectations or speculative interest.

Is Orchid Pharma Ltd financially healthy?

Key indicators for Orchid Pharma Ltd: ROCE of 8.07 % is on the lower side compared to the industry average of 16.35%. Dividend yield is 0.00 %.

Is Orchid Pharma Ltd profitable and how is the profit trend?

Orchid Pharma Ltd reported a net profit of ₹100 Cr in Mar 2025 on revenue of ₹922 Cr. Compared to ₹-2 Cr in Mar 2022, the net profit shows an improving trend.

Does Orchid Pharma Ltd pay dividends?

Orchid Pharma Ltd has a dividend yield of 0.00 % at the current price of ₹519.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Orchid Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports